Trial
NCT02392377
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Stage IB Esophageal Adenocarcinoma
Intervention
Paclitaxel
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-13